These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32948146)

  • 1. Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.
    Kubo A; Hidaka T; Nakayama M; Sasaki Y; Takagi M; Suzuki H; Suzuki Y
    BMC Nephrol; 2020 Sep; 21(1):402. PubMed ID: 32948146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
    Uchii M; Kimoto N; Sakai M; Kitayama T; Kunori S
    Eur J Pharmacol; 2016 Jul; 783():56-63. PubMed ID: 27063445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
    Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
    Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo.
    Uchii M; Sakai M; Hotta Y; Saeki S; Kimoto N; Hamaguchi A; Kitayama T; Kunori S
    J Pharmacol Sci; 2017 Nov; 135(3):126-130. PubMed ID: 29113790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
    Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS
    J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.
    Jung E; Kim J; Ho Kim S; Kim S; Cho MH
    Eur J Pharmacol; 2015 Aug; 761():116-24. PubMed ID: 25977232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
    Gangadharan Komala M; Gross S; Zaky A; Pollock C; Panchapakesan U
    Nephrology (Carlton); 2016 May; 21(5):423-31. PubMed ID: 26375854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial podocyte replenishment in experimental FSGS derives from nonpodocyte sources.
    Kaverina NV; Eng DG; Schneider RR; Pippin JW; Shankland SJ
    Am J Physiol Renal Physiol; 2016 Jun; 310(11):F1397-413. PubMed ID: 27076646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
    Takashima S; Fujita H; Fujishima H; Shimizu T; Sato T; Morii T; Tsukiyama K; Narita T; Takahashi T; Drucker DJ; Seino Y; Yamada Y
    Kidney Int; 2016 Oct; 90(4):783-96. PubMed ID: 27475229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saxagliptin attenuates glomerular podocyte injury by increasing the expression of renal nephrin and podocin in type 2 diabetic rats.
    Hu Y; Ye S; Xing Y; Lv L; Hu W; Zhou W
    Acta Diabetol; 2020 Mar; 57(3):279-286. PubMed ID: 31535208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin.
    Dong J; Gong Y; Liu J; Chen X; Wen X; Sun H
    Bioorg Med Chem; 2014 Feb; 22(4):1383-93. PubMed ID: 24457090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury.
    Eun Lee J; Kim JE; Lee MH; Song HK; Ghee JY; Kang YS; Min HS; Kim HW; Cha JJ; Han JY; Han SY; Cha DR
    Lab Invest; 2016 May; 96(5):547-60. PubMed ID: 26878135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
    Boulton DW
    Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.
    Nicotera R; Casarella A; Longhitano E; Bolignano D; Andreucci M; De Sarro G; Cernaro V; Russo E; Coppolino G
    Pharmacol Res; 2020 Sep; 159():105019. PubMed ID: 32553713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regeneration of glomerular podocytes by human renal progenitors.
    Ronconi E; Sagrinati C; Angelotti ML; Lazzeri E; Mazzinghi B; Ballerini L; Parente E; Becherucci F; Gacci M; Carini M; Maggi E; Serio M; Vannelli GB; Lasagni L; Romagnani S; Romagnani P
    J Am Soc Nephrol; 2009 Feb; 20(2):322-32. PubMed ID: 19092120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.
    Gupta S; Sen U
    Pharmacol Res; 2019 Sep; 147():104391. PubMed ID: 31401210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble RARRES1 induces podocyte apoptosis to promote glomerular disease progression.
    Chen A; Feng Y; Lai H; Ju W; Li Z; Li Y; Wang A; Hong Q; Zhong F; Wei C; Fu J; Guan T; Liu B; Kretzler M; Lee K; He JC
    J Clin Invest; 2020 Oct; 130(10):5523-5535. PubMed ID: 32634130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.